An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Big change in one sentence: since the patent on semaglutide expired in March, India has seen the price of that drug fall by about 80%, and the market for GLP‑1 drugs there has grown roughly tenfold in a year. Semaglutide is the active ingredient in popular weight-loss and diabetes medicines like Ozempic and Wegovy. In simple terms, it is a man-made version of a hormone your gut releases after you eat. That hormone tells your brain you’re full and slows how fast food leaves your stomach, which can help people eat less and control blood sugar. It’s not a magic pill — it’s a drug that changes signals between the gut and the brain. What the report actually says is about markets and prices, not a new medical study. When the patent expired, other drug makers in India were able to produce generic versions of semaglutide. Competition drove prices down — the report cites an 80% drop — and more products became available, so sales jumped: the GLP‑1 category (the family of drugs that act like that gut hormone) expanded roughly tenfold over a year. This is an economic and access story, based on market data, not new clinical evidence about how well the drug works. Why it matters to regular people: cheaper generics can make proven medicines accessible to many more people, especially in countries where branded versions are unaffordable. For patients with diabetes, obesity, or doctors trying to treat those conditions, lower prices and more suppliers can mean more options and lower out‑of‑pocket costs. It can also affect global supply and the strategies of big drug companies, possibly lowering prices in other markets over time. Caveats and risks: the snippet is about price and market size, not safety or effectiveness. Generics must be made to the same quality standards as the original, but manufacturing and regulatory oversight matter. Semaglutide has known side effects, like nausea, stomach discomfort, and rare but serious risks for some people; it should be used under medical supervision. Patent expiry in one country doesn’t automatically change availability or price everywhere, and regulatory approvals still apply before new versions can be sold. Bottom line: patent expiry in India appears to have sharply cut prices and sharply increased access to semaglutide-class drugs there, which could help many people afford treatment — but medical and regulatory caution still applies.
Source: facebook.com